A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors (PROPEL-36)

ektar Therapeutics0 个研究点目标入组 0 人开始时间: 2021年10月8日最近更新: 2023年10月9日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Provide written, informed consent to participate in the study and follow the study procedures.
•Male or female patients, age 18 years or older on the day of signing the informed consent form.
•Have histologically or cytologically-confirmed recurrent or metastatic HNSCC that is considered incurable by local therapies.
•o No prior systemic therapy for recurrent or metastatic disease. Systemic therapy given as part of multimodal treatment for locally advanced disease is allowed if completed more than 6 months prior to signing consent.
•o The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
•o Patients may not have a primary tumor site of nasopharynx (any histology) and/or unknown primary.
•Have measurable disease based on RECIST 1.1 as determined by the local site Investigator. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions since irradiation.
•Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
•Tumor tissue from a core, incisional, or excisional biopsy (fine needle aspirates are not acceptable) to the central laboratory for determination of PD-L1 status (if not determined at local laboratory) and exploratory biomarker analyses. A newly obtained biopsy is strongly preferred, but archival tumor biopsy may be used and provided (see Section 8.3.1).
•The tumor must have positive PD-L1 expression (ie, CPS = 1) as determined with the PD-L1 IHC 22C3 PharmDx diagnostic kit at either a local or central laboratory.
•Patients with oropharyngeal cancer: must have results from testing of HPV status defined as p16 IHC testing using CINtec® p16 Histology assay (Ventana Medical Systems Inc., Tucson AZ). If HPV status was previously tested using this method, no additional testing is required. Note: If local p16 testing results are not available, or cannot be assessed by the specified method, a tumor tissue sample may be submitted to the central laboratory for p16 testing. Patients with oral cavity, hypopharynx, or larynx cancers: HPV testing by p16 IHC is not required as by convention these tumor locations are assumed to be HPV negative.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 320
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 180

排除标准

•Has disease that is suitable for local therapy administered with curative intent.
•Has progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
•Has had radiation therapy (or other non-systemic therapy) within 2 weeks prior to initiation of study drug, or patient has not fully recovered (ie, = Grade 1 or at baseline) from AEs due to a previously administered treatment. A 1-week washout is permitted for palliative radiation (= 2 weeks of radiotherapy) to non-central nervous system (CNS) disease. Note:
•o Patients with = Grade 2 neuropathy or = Grade 2 alopecia are an exception to this criterion and qualify for the study.
•o If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
•Has a life expectancy of less than 3 months and/or has rapidly progressing disease (eg, tumor bleeding, uncontrolled tumor pain) as determined by Investigator.
•Has a known additional malignancy that is progressing or has required active treatment within 5 years prior to the first dose of study drug with the exception of: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, curatively resected in situ cervical cancer, and curatively resected in situ breast cancer.
•Has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
•Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. Corticosteroid use as pre-medication for allergic reactions (eg, intravenous [IV] contrast) is allowed. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.

研究者

发起方

ektar Therapeutics

相似试验

进行中（未招募）

1 期

Bempegaldesleukin with pembrolizumab in patients with PD-L1 (programmed cell death-ligand 1) positive Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma (HNSCC).

EUCTR2021-002461-18-ITEKTAR THERAPEUTICS

进行中（未招募）

2 期

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCCRecurrent or metastatic head and neck cancerPD-L1 expression positive

JPRN-jRCT2031220385Sato Toshiyuki54

进行中（未招募）

1 期

Bempegaldesleukin with pembrolizumab in patients with PD-L1 (programmed cell death-ligand 1) positive Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma (HNSCC).Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing TumorsMedDRA version: 22.0Level: LLTClassification code 10082179Term: Squamous cell carcinoma of head and neck metastaticSystem Organ Class: 100000004864

EUCTR2021-002461-18-NLektar Therapeutics500

进行中（未招募）

1 期

EUCTR2021-002461-18-GRektar Therapeutics500

进行中（未招募）

1 期

Bempegaldesleukin with pembrolizumab in patients with PD-L1 (programmed cell death-ligand 1) positive Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma (HNSCC).

EUCTR2021-002461-18-BEektar Therapeutics500